SCHEMBL4906728

SCHEMBL4906728

CN(Cc1c(-c2ccccc2)nc2ccccc2c1C(=O)O)C1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 2/20 0.51
TSHR P16473 1/20 0.51
TACR3 P29371 12/20 0.50
LMNA P02545 2/20 0.50
POLB P06746 1/20 0.50
TACR2 P21452 8/20 0.49
DHODH Q02127 3/20 0.49
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
OPRM1 P35372 5/20 0.47
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
NSD2 O96028 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MPI P34949 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6853585 0.88 POLB (0.48) PDE10ATSHRTACR3LMNAPOLB
SCHEMBL6853322 0.84 TACR3 (0.51) PDE10ATSHRTACR3LMNAPOLB
SCHEMBL6200397 0.84 PDE10A (0.48) PDE10ATSHRTACR3LMNAPOLB
SCHEMBL4665929 0.81 TACR3 (0.64) PDE10ATSHRTACR3LMNAPOLB
SCHEMBL8267077 0.79 PDE10A (0.59) PDE10ATSHRTACR3LMNAPOLB
SCHEMBL7691041 0.77 PDE10A (0.57) PDE10ATSHRTACR3LMNAPOLB
SCHEMBL8268035 0.77 PDE10A (0.53) PDE10ATSHRTACR3LMNAPOLB
SCHEMBL8268023 0.76 PDE10A (0.56) PDE10ATSHRTACR3LMNAPOLB
SCHEMBL4906729 0.76 DHODH (0.50) PDE10ATSHRTACR3LMNAPOLB
SCHEMBL6363272 0.75 TACR3 (0.62) TACR3TACR2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096885-A1 Quinoline Derivatives as Neurokinin Receptor Antagonists MERCK SHARP & DOHME LTD. (GB) 2008-04-24 US claimed
EP-1776344-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-04-25 EP claimed
WO-2006013393-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-02-09 WO claimed
US-20080096885-A1 Quinoline Derivatives as Neurokinin Receptor Antagonists MERCK SHARP & DOHME LTD. (GB) 2008-04-24 US disclosed
EP-1776344-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-04-25 EP disclosed
WO-2006013393-A2 QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096885-A1 Quinoline Derivatives as Neurokinin Receptor Antagonists TACR3, TACR2, TAC3 PDE10A 2172/4885TSHR 785/4885TACR3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.